Pharmacokinetics: Phase I and Phase II Biotransformation Reactions

Introduction

Biotransformation, also referred to as drug metabolism, constitutes a fundamental component of pharmacokinetics. It encompasses the enzymatic and non‑enzymatic processes that convert lipophilic parent compounds into more hydrophilic metabolites, thereby facilitating excretion. The division of biotransformation into Phase I and Phase II reactions provides a conceptual framework that has guided drug development, therapeutic monitoring, and clinical decision‑making for decades.

Historically, the recognition of metabolic pathways dates back to the early 20th century, when the first cytochrome P450 enzymes were identified. Subsequent advances in molecular biology and analytical chemistry have expanded the catalog of metabolic enzymes and clarified the mechanistic underpinnings of drug disposition. The clinical relevance of these pathways is evident in drug–drug interactions, inter‑individual variability, and the emergence of personalized medicine.

Learning objectives for this chapter include:

• Describe the biochemical characteristics of Phase I and Phase II reactions.
• Explain the enzymatic systems responsible for each phase and their regulatory mechanisms.
• Apply kinetic models to predict metabolic rates and clearance.
• Identify factors that influence biotransformation, including genetics, age, disease, and concomitant medications.
• Integrate knowledge of metabolic pathways into clinical scenarios to optimize drug therapy.

Fundamental Principles

Core Concepts and Definitions

Biotransformation is defined as the alteration of a chemical compound by a biological system. In pharmacology, it refers to the conversion of administered drugs into metabolites. The process is typically divided into two sequential phases:

• Phase I reactions introduce or expose functional groups through oxidation, reduction, or hydrolysis.
• Phase II reactions conjugate the modified substrate with endogenous molecules, enhancing solubility.

Key terminology includes:

• Substrate – the parent drug undergoing metabolism.
• Metabolite – the product of biotransformation.
• Enzyme induction – up‑regulation of enzyme expression.
• Enzyme inhibition – suppression of enzyme activity.
• Genotype – inherited variation in metabolic enzyme genes.
• Phenotype – the observable metabolic capacity.

Theoretical Foundations

Metabolic reactions are governed by enzyme kinetics. The Michaelis–Menten equation describes the relationship between substrate concentration and reaction velocity:

V = (V_max × [S]) / (K_m + [S])

where V is the reaction rate, V_max is the maximum velocity, [S] is the substrate concentration, and K_m is the substrate concentration at half V_max. For many drugs, the concentration achieved in vivo is below K_m, allowing linear kinetics to be assumed. However, saturable metabolism can occur at therapeutic or supratherapeutic levels, leading to nonlinear pharmacokinetics.

Clearance (CL) is a central pharmacokinetic parameter reflecting the efficiency of drug elimination. It is defined as the volume of plasma from which the drug is completely removed per unit time:

CL = V_d × k

where V_d is the apparent volume of distribution and k is the elimination rate constant. The half‑life (t_1/2) of a drug is related to clearance and volume of distribution by:

t_1/2 = 0.693 × V_d / CL

These relationships provide a quantitative framework for predicting how alterations in metabolic capacity influence drug exposure.

Detailed Explanation

Phase I Reactions

Phase I reactions primarily involve the introduction or unmasking of polar functional groups. The most common mechanisms are oxidation, reduction, and hydrolysis. The cytochrome P450 (CYP) enzyme family dominates oxidative metabolism, accounting for approximately 75% of drug biotransformation. Other oxidases, such as flavin-containing monooxygenases (FMOs), also contribute, particularly for substrates with heteroatoms.

Oxidative reactions typically proceed via the insertion of an oxygen atom into the substrate, generating alcohols, ketones, aldehydes, or carboxylic acids. Reduction reactions, mediated by enzymes such as NADPH‑dependent reductases, convert double bonds or carbonyl groups to saturated structures. Hydrolytic reactions, catalyzed by esterases and amidases, cleave ester or amide bonds, yielding carboxylic acids or amines.

Key CYP isoforms relevant to drug metabolism include CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2. Each isoform exhibits distinct substrate specificity and regulatory patterns. For instance, CYP3A4 is highly inducible by rifampicin and inhibited by ketoconazole, whereas CYP2D6 displays extensive genetic polymorphism, leading to poor, intermediate, extensive, or ultra‑rapid metabolizer phenotypes.

Phase II Reactions

Phase II reactions involve conjugation of the Phase I metabolite (or, less frequently, the parent drug) with endogenous donors, thereby increasing hydrophilicity and facilitating renal or biliary excretion. The principal conjugation reactions are glucuronidation, sulfation, acetylation, glutathione conjugation, and methylation.

Glucuronidation, mediated by UDP‑glucuronosyltransferases (UGTs), attaches glucuronic acid to hydroxyl, carboxyl, or amine groups. Sulfation, catalyzed by sulfotransferases (SULTs), transfers a sulfonate group to phenolic or amine substrates. Acetylation, performed by N‑acetyltransferases (NATs), modifies arylamine or hydrazine moieties. Glutathione conjugation, facilitated by glutathione S‑transferases (GSTs), is a critical detoxification pathway for electrophilic compounds. Methylation, mediated by catechol O‑methyltransferase (COMT) and other methyltransferases, transfers a methyl group from S‑adenosyl‑methionine to hydroxyl or amine groups.

Phase II reactions are generally saturable and may be inhibited by endogenous or exogenous substances. For example, high concentrations of bilirubin can competitively inhibit UGTs, while certain drugs (e.g., sulfonamides) can inhibit SULTs.

Mathematical Relationships and Models

In vitro–in vivo extrapolation (IVIVE) is frequently employed to predict in vivo clearance from in vitro data. The basic IVIVE equation is:

CL_{in vivo} = (CL_int × f_u × Q) / (CL_int × f_u + Q)

where CL_int is the intrinsic clearance measured in vitro, f_u is the fraction unbound in plasma, and Q is hepatic blood flow. When CL_int is much lower than Q, hepatic clearance approximates CL_int × f_u. Conversely, when CL_int is high, hepatic clearance approaches Q.

For drugs undergoing both Phase I and Phase II metabolism, the overall clearance can be approximated by the parallel clearance model:

CL_total = CL_{Phase I} + CL_{Phase II}

However, sequential metabolism (Phase I followed by Phase II) requires consideration of the rate‑limiting step, often the slower of the two phases.

Factors Affecting Biotransformation

Multiple variables modulate metabolic capacity:

• Genetic polymorphisms – Variants in CYP2D6, CYP2C19, UGT1A1, and other genes alter enzyme activity.
• Age – Neonates exhibit immature CYP3A7 activity; elderly patients may have reduced hepatic blood flow.
• Sex – Hormonal differences can influence CYP expression.
• Disease states – Hepatic impairment reduces enzyme abundance; inflammatory cytokines can down‑regulate CYPs.
• Drug interactions – Inducers (e.g., rifampicin) increase enzyme expression; inhibitors (e.g., ketoconazole) decrease activity.
• Dietary components – Grapefruit juice inhibits CYP3A4; cruciferous vegetables induce CYP1A2.
• Environmental exposures – Tobacco smoke induces CYP1A2; alcohol induces CYP2E1.

Clinical Significance

Understanding Phase I and Phase II metabolism is essential for predicting drug efficacy, toxicity, and interactions. For instance, the analgesic effect of codeine depends on CYP2D6‑mediated conversion to morphine; poor metabolizers may experience inadequate pain control, whereas ultra‑rapid metabolizers risk morphine toxicity. Similarly, acetaminophen overdose leads to accumulation of the toxic metabolite N‑acetyl‑p‑benzoquinone imine (NAPQI), which is normally detoxified by glutathione conjugation. In patients with impaired glutathione stores, hepatotoxicity ensues.

Drug interactions frequently arise from competition for the same metabolic pathway. Warfarin, metabolized by CYP2C9, can have its anticoagulant effect potentiated by inhibitors such as fluconazole, necessitating dose adjustment. Conversely, rifampicin, a potent CYP3A4 inducer, can reduce the plasma concentration of protease inhibitors, compromising HIV therapy.

Phase II reactions also influence drug disposition. For example, the antiepileptic drug valproic acid undergoes glucuronidation; inhibition of UGT1A4 by valproic acid itself can lead to accumulation of other drugs metabolized by the same enzyme, such as phenytoin.

Clinical Applications/Examples

Case Scenario 1: Codeine and CYP2D6 Polymorphism

A 45‑year‑old woman presents with postoperative pain and is prescribed codeine. She reports minimal analgesic benefit. Genetic testing reveals a CYP2D6 poor metabolizer genotype. The lack of conversion to morphine explains the inadequate response. Switching to a non‑opioid analgesic or a drug not requiring CYP2D6 activation (e.g., tramadol) would be more appropriate.

Case Scenario 2: Acetaminophen Overdose and Glutathione Conjugation

A 30‑year‑old man ingests 10 g of acetaminophen. Serum NAPQI levels are elevated, and hepatic function tests are abnormal. The patient receives N‑acetylcysteine, which replenishes glutathione stores, facilitating detoxification of NAPQI. Early intervention prevents progression to fulminant hepatic failure.

Case Scenario 3: Rifampicin Induction of CYP3A4

A 55‑year‑old man with HIV is on a protease inhibitor regimen. Rifampicin is added to treat a concurrent tuberculosis infection. The induction of CYP3A4 accelerates protease inhibitor metabolism, reducing plasma concentrations below therapeutic thresholds. Dose escalation or alternative antitubercular therapy is required to maintain virologic suppression.

Problem‑Solving Approach

1. Identify the primary metabolic pathway of the drug (Phase I vs. Phase II).
2. Determine the relevant enzymes and assess potential genetic or phenotypic variability.
3. Evaluate concomitant medications for inhibitory or inductive effects.
4. Consider disease states that may alter enzyme expression or hepatic blood flow.
5. Apply kinetic models to estimate changes in clearance and adjust dosing accordingly.

Summary / Key Points

• Biotransformation is divided into Phase I (functionalization) and Phase II (conjugation) reactions.
• CYP450 enzymes dominate Phase I oxidation; UGTs, SULTs, NATs, GSTs, and COMT mediate Phase II conjugation.
• Michaelis–Menten kinetics describe enzyme activity; clearance and half‑life are linked to volume of distribution and elimination rate constant.
• Genetic polymorphisms, age, disease, diet, and drug interactions significantly influence metabolic capacity.
• Clinical examples illustrate the impact of metabolism on efficacy, toxicity, and drug interactions.
• Therapeutic drug monitoring and genotype testing can guide individualized dosing.
• Early recognition of metabolic impairment or interaction risk can prevent adverse outcomes.

Clinical pearls:

• When prescribing drugs with narrow therapeutic indices, consider metabolic pathways and potential interactions.
• In patients with hepatic impairment, anticipate reduced Phase I and Phase II capacity; dose reductions or alternative agents may be necessary.
• For drugs requiring metabolic activation (e.g., codeine), confirm metabolic competence before initiating therapy.
• Monitor for signs of toxicity in drugs that produce reactive metabolites (e.g., acetaminophen, isoniazid).
• Use pharmacogenomic testing selectively to guide therapy in high
  

  References

  1. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 7th ed. New York: McGraw-Hill Education; 2016.
  2. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Philadelphia: Wolters Kluwer; 2011.
  3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
  4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
  5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
  6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
  7. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
  8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.

  ⚠️ Medical Disclaimer

  This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

  The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.